ScreenerHero

DSGN Design Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · designtx.com
11.69USD-2.34%Mkt Cap: 731.58M $P/E: —

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The compa…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap731.58M USD
Enterprise Value544.37M USD
Revenue (TTM)—
Gross Profit-58.78M USD
Net Income (TTM)-69.79M USD
Revenue/Share—
Last Price11.69 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.39
PEG—
EV/EBITDA-6.95
EV/Revenue—
P/S—
P/B3.71
EPS (TTM)-1.14
EPS (Forward)-1.62
52W Range
5.28054% of range17.25
52W High17.25 USD
52W Low5.280 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.84%
ROA-30.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)193.00K USD
FCF Margin—
FCF Yield-4.42%
Net Debt-204.73M USD
Net Debt/EBITDA2.61
Balance Sheet
Debt/Equity0.01
Current Ratio18.86
Quick Ratio18.61
Book Value/Sh3.23 USD
Cash/Share3.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.71 USD
Upside (mean)+85.8%
Target Range20.00 USD – 26.00 USD
20.00+85.8% to mean26.00
# Analysts7
Ownership
Shares Out.62.58M
Float36.19M
Insiders31.87%
Institutions78.64%
Short Interest
Short Ratio7.9d
Short % Float11.56%
Short % Out.8.73%
Shares Short5.46M
Short (prev mo.)5.93M
Technical
SMA 5013.81 (-15.3%)
SMA 20012.04 (-2.9%)
Beta1.69
S&P 52W Chg16.45%
Avg Vol (30d)683.42K
Avg Vol (10d)541.06K
Technical Indicators
RSI (14)34.4
MACD-0.5499
MACD Signal-0.4629
MACD Hist.-0.0870
BB Upper15.12 USD
BB Middle12.92 USD
BB Lower10.71 USD
BB Width34.16%
ATR (14)0.6846 USD
Vol Ratio (20d)0.47x